Follow The Filings

BNGO Bionano Genomics

Bionano Genomics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by BNGO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BNGO insider trades
  • $9,705 bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Albert Luderer CEO
    Buy
    $4,845 4,000 shares at $1.21 +100% to stake
    Traded Sep 4 Filed Sep 9
  2. Albert Luderer CEO
    Buy
    $4,860 4,000 shares at $1.22 New stake
    Traded Aug 21 Filed Aug 21

Also filed in the last 12 months, not counted as buying or selling: 9 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
SCHEDULE 13G —
8-K 7.01,9.01
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 8.01,9.01
8-K 5.02
8-K 8.01,9.01
8-K 5.07
8-K 2.02,9.01
10-Q
8-K 5.02,8.01,9.01
DEF 14A
DEFA14A
8-K 2.02,9.01
10-K
SCHEDULE 13G/A —
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.